Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-22, Stock:LLY, The news for the past five days is as follows:
2018-05-15: NEWS1: MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads.NEWS2: MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads.NEWS3: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS4: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS5: Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline.NEWS6: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2018.NEWS7: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2018.NEWS8: An Update on Teva’s Highly Anticipated Migraine Drug.NEWS9: Star Kleiner Perkins VC may be launching her own firm.NEWS10: An Overview of Valeant Pharmaceuticals’ Performance in 1Q18.NEWS11: Eli Lilly's cluster-headache treatment passes phase 3 test.NEWS12: Eli Lilly's cluster-headache treatment passes phase 3 test.NEWS13: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache.NEWS14: Lilly's migraine drug meets main goal in cluster headache trial.NEWS15: Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts.NEWS16: Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts.
2018-05-16: NEWS1: Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care.NEWS2: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS3: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS4: iShares Core High Dividend ETF Experiences Big Outflow.NEWS5: iShares Core High Dividend ETF Experiences Big Outflow.NEWS6: Eli Lilly&apos;s Cluster Headache Candidate Succeeds in Phase III.NEWS7: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.NEWS8: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.
2018-05-17: NEWS1: U.S. FDA approves Amgen migraine drug, price set at $6900/yr.NEWS2: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS3: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS4: Exelixis Is Expected to Report a Robust Revenue Rise in 2018.NEWS5: Teva’s Fiscal Guidance: Confidence in Its Growth.NEWS6: Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache.
2018-05-18: NEWS1: Eli Lilly’s Business Segments in Q1 2018.NEWS2: Eli Lilly’s Revenue Trend in Q1 2018.NEWS3: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS4: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS5: Eli Lilly’s Valuation on May 17.NEWS6: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS7: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS8: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS9: AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS10: AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS11: Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug.NEWS12: AstraZeneca&apos;s (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS13: 5 Things AbbVie Investors Need to Know.NEWS14: 5 Things AbbVie Investors Need to Know.
2018-05-21: NEWS1: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS2: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS3: Eli Lilly’s Neuroscience Products in Q1 2018.NEWS4: Eli Lilly’s Human Pharmaceuticals Business in Q1 2018.NEWS5: Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space.

Answer: Rise